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3 
SUMMARY 68 
 69 
Patients with Chronic Mucocutaneous Candidiasis (CMC) have an unknown primary immune 70 
defect and are unable to clear infections with the yeast Candida. CMC includes patients with 71 
AIRE gene mutations who have Autoimmune PolyEndocrinopathy Candidiasis Ectodermal 72 
Dystrophy (APECED), and patients without known mutations. CMC patients have dysregulated 73 
cytokine production, suggesting that defective expression of pattern recognition receptors 74 
(PRRs) may underlie disease pathogenesis. In 29 patients with CMC (13 with APECED) and 75 
controls, we assessed dendritic cell (DC) subsets and monocyte Toll-like receptor (TLR) 76 
expression in blood. We generated and stimulated monocyte-derived (mo)DCs with Candida 77 
albicans, TLR2/6- ligand and lipopolysaccharide and assessed PRR mRNA expression by PCR 78 
(TLR1-10, Dectin-1 & 2, Syk and CARD9) in immature and mature moDCs. We demonstrate 79 
for the first time that CMC patients, with or without APECED have normal blood levels of 80 
plasmocytoid and myeloid DCs and monocyte TLR2 / TLR6 expression. We showed that in 81 
immature moDCs, expression levels of all PRRs involved in anti-Candida responses (TLR1, 2, 82 
4, 6, Dectin-1, Syk, CARD9) were comparable to controls, implying that defects in PRR 83 
expression are not responsible for the increased susceptibility to Candida infections seen in 84 
CMC patients.  However, as opposed to healthy controls, both groups of CMC patients failed to 85 
downregulate PRR mRNA expression in response to Candida, consistent with defective DC 86 
maturation, as we recently reported. Thus, impaired DC maturation and consequent altered 87 
regulation of PRR signalling pathways rather than defects in PRR expression may be responsible 88 
for inadequate Candida handling in CMC patients. 89 
 90 
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4 
INTRODUCTION 91 
Pattern recognition receptors (PRRs) on cells of the innate immune system recognise core 92 
structures specific to microorganisms (pathogen associated molecular patterns or PAMPS) that 93 
are alien to mammals [1], [2]. Toll-like receptors (TLR), particularly TLR 1, 2, 4 and 6 and C-94 
type lectin receptors (CLRs) such as Dectin-1 and 2, mannose receptor (MR) and dendritic cell-95 
specific intercellular adhesion molecule-3 (ICAM-3)-grabbing non-integrin (DC-SIGN) are 96 
known to be important PRRs in fungal recognition, initiating immune responses to these 97 
pathogens [3]. More recently, complex interactions and collaboration of these receptors through 98 
formation of heterodimers have been demonstrated to modulate immune responses to different 99 
fungi [4]. 100 
In mice, activation of TLR4 initiates interleukin (IL)-12 production by dendritic cells 101 
(DCs) generating a protective Th1 response. In contrast, activation of TLR2 mediates a non-102 
protective Th2 response via IL-10 production and generation of T regulatory cells [5]. TLR1 and 103 
TLR6 form heterodimers with TLR2 modulating the Th1/Th2 balance in response to fungi [6], 104 
while Dectin-1 synergizes with TLR2 and TLR4 for cytokine production [7]. However, humans 105 
with inborn errors of the IL-12/IFNγ pathway do not show increased susceptibility to Candida or 106 
other fungal infections [8], suggesting that this pathway might not have the same importance in 107 
fungal defences in humans as in mice. Recent evidence suggests that the Th-17 pathway is 108 
crucially involved in immune response to fungi [9]. Dectin-1 signalling through a non-TLR 109 
signalling pathway that involves the spleen tyrosine kinase (Syk) and adaptor caspase 110 
recruitment domain (CARD) 9 [10], primes dendritic cells to “instruct” differentiation of CD4+ 111 
IL-17 producing effector T cells, demonstrating a direct link between the innate and adaptive 112 
immune system [11] in generating protective fungal responses.  113 
Chronic Mucocutaneous Candidiasis (CMC) is a primary immunodeficiency disorder 114 
(PID) with selective susceptibility to recurring and/or persistent, debilitating infections with the 115 
yeast Candida [12] and includes several subtypes. The APECED syndrome (Autoimmune 116 
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5 
PolyEndocrinopathy Candidiasis Ectodermal Dystrophy), also known as APS1 (Autoimmune 117 
PolyEndocrinopathy Type 1) is associated with organ-specific autoimmune involvement of 118 
particularly the endocrine glands and an underlying mutation of the AIRE gene (Online 119 
Mendelian Inheritance in Man - OMIM 240300). Other subgroups of CMC include patients with 120 
associated thyroid disease but no other autoimmunity (OMIM 606415), isolated CMC with 121 
various modes of inheritance (OMIM 11458, OMIM 212050) and sporadic CMC. In these CMC 122 
patients the diagnosis remains clinical, given that a genetic or biochemical marker is not yet 123 
available.   124 
Very little is known about the immune defect underlying increased susceptibility to 125 
Candida infections in CMC patients. Previously, we demonstrated dysregulated cytokine 126 
production in response to Candida [12] suggesting that the immune defect might be at the level 127 
of orchestrating appropriate cytokine responses, rather than the effector T cell level itself.  128 
Our assumption that defects of PRRs, which can recognise moeities from many different 129 
organisms, could specifically cause an immune defect against Candidas is based on the recent 130 
recognition of similar scenarios underlying non-conventional primary immune deficiencies 131 
(PIDs), defined as a selective susceptibility to a single weakly pathogenic or opportunistic 132 
organism. Surprisingly, in these PIDs, a predisposition to a single type of infection is caused by 133 
immune defects affecting pathways central to the immune response. Examples include disorders 134 
of the interleukin (IL)-12/interferon (IFN)γ circuit resulting in selective susceptibility to 135 
infections with mycobacteria and Salmonella; defects in the TLR3  pathway resulting in selective 136 
predisposition to Herpes Simplex Infection; MyD88 deficiency and susceptibility to pyogenic 137 
bacterial infections. The infectious phenotype that the above disorders confer in humans is much 138 
narrower than those of corresponding mutant mice, suggesting there is much redundancy in 139 
human host defence in nature [13], [14]. In analogy, given that DCs are central initiators of 140 
immune responses, while PRRs and TLRs are known to be involved in production of cytokines 141 
in protective Candida immunity, we hypothesised that reduced DC numbers and/or a defect of 142 
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6 
pattern recognition receptors involved in immune responses to Candida might underlie a 143 
selective susceptibility to this microorganism in patients with CMC.  144 
In CMC patients and age-and-gender matched healthy controls, we investigated the 145 
proportion of DCs and DC subsets in peripheral blood, as well as TLR receptor expression on 146 
blood monocytes; we then isolated monocytes from peripheral blood and cultivated them in-vitro 147 
into monocyte-derived DCs (moDCs), which we stimulated / matured with Candida and other 148 
relevant antigens to assess expression of TLR1-10, Dectin-1 and 2, CARD9 and Syk.. We 149 
demonstrate for the first time that CMC patients, with or without APECED have normal blood 150 
levels of plasmocytoid and myeloid DCs and monocyte TLR2 / TLR6 expression. In immature 151 
moDCs, expression levels of all PRRs involved in anti-Candida responses (TLR1, 2, 4, 6, 152 
Dectin-1, Syk, CARD9) were comparable to controls. However, as opposed to healthy controls, 153 
both groups of CMC patients failed to downregulate PRR mRNA expression in response to 154 
Candida, suggesting that impaired DC maturation and consequently altered regulation of PRR 155 
signalling pathways rather than defects in PR  themselves may be responsible for inadequate 156 
Candida handling in CMC patients.  157 
These results complement our previous report of impaired DC maturation, where 158 
activation and function of these same DCs was investigated in parallel through cytokine 159 
production and cell surface marker expression, which is presented in a separate publication [15].  160 
 161 
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7 
MATERIALS AND METHODS 162 
General conditions 163 
Monocyte-derived DCs were used as representatives of skin and mucosal myeloid-DCs 164 
involved in Candida recognition, because obtaining skin biopsies from CMC patients for purely 165 
research purposes was not deemed acceptable for ethical reasons.  166 
We stimulated moDCs with Candida albicans hyphae (CH) rather than yeasts, as several 167 
studies suggest that hyphae are the invasive morphotype of Candida in clinical infections [16]. 168 
With the aim of investigating putative impaired Candida binding to DCs, we assessed moDC 169 
stimulation with a Toll-like receptor (TLR) ligand 2/6 (MALP2) that selectively engages the 170 
same TLRs that are known to bind Candida and other yeasts [17]. Lipopolysaccharide (LPS) was 171 
used as a “positive” non-Candida control, in order to assess moDC functionality in response to 172 
other potent stimuli. Repeat assessments and inclusion of additional stimuli were limited by the 173 
quantity of blood we could draw from each patient, particularly children. 174 
 175 
Subjects 176 
Patients: We studied 29 patients with CMC, 13 APECED with a confirmed AIRE gene mutation 177 
and 16 non-APECED without. All patients were screened for the two most common AIRE gene 178 
mutations: p.R257X (a nonsense mutation in exon 6) and c.964del13 (a 13bp deletion in exon 8) 179 
(Huch-Laboratory Diagnostics, Helsinki University Hospital, Finland and Northern Molecular 180 
Genetics Service, Institute of Human Genetics, Newcastle Upon Tyne, UK).  Thirteen patients 181 
were found to have an AIRE gene mutation and the APECED syndrome, of which 9 had the 182 
c.964del13 deletion and 4 had the p.R257X mutation. In the remaining 16 non-APECED patients 183 
an AIRE mutation was not detected. None of the patients without the AIRE gene mutation had 184 
any clinical signs suggestive of APECED that would justify investigations of additional AIRE 185 
gene mutations. All patients were screened for autoantibodies to type 1 interferons (IFNs) which 186 
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8 
were recently shown to be highly specific for APECED patients [18]; these autoantibodies were 187 
present in all APECED patients and none of the non-APECED patients and controls.  188 
In the APECED group, 10 patients had affected siblings and 9 in the non-APECED 189 
group, which are all included in this study.  Three patients from the latter group had 190 
hypothyroidism, 2 with thyroid peroxidase antibodies. Not more than 3 patients from any one 191 
family were studied. At the time of sampling, patients did not have any other serious infections, 192 
were not on systemic antibiotic treatment or receiving steroids. All patients suffered from 193 
recurrent mucocutaneous Candida infection (mouth, nails, skin, oesophagus and perineum), but 194 
no other fungal infections including dermatophyte (e.g. tinea corporis) infections. Patients were 195 
screened for systemic autoantibodies (AAbs) including antinuclear factor, smooth muscle, liver-196 
kidney microsomal, mitochondrial and gastric parietal cell antibodies. Systemic AAbs were 197 
found in 4/13 APECED patients and 5/16 non-APECED patients. Organ-specific autoantibodies 198 
and/or endocrinopathy were observed in one or more of the following organs: parathyroid, 199 
thyroid, adrenal cortex, gonads and pancreas. Autoantibodies were evaluated in patients sera 200 
using indirect immunofluorescence on commercial rodent tissue (Euroimmune, Lubeck, 201 
Germany) for systemic autoantibodies and monkey organ tissue (The Binding Sire, Birmingham, 202 
UK) for organ-specific autoantibodes. Endocrinopathy was diagnosed if/when there was clinical 203 
and laboratory evidence of glandular hypofunction. 204 
Controls: 25 age-and-sex matched controls were recruited for the study.  Adults were healthy 205 
laboratory volunteers, while control children were undergoing general anaesthesia for surgery to 206 
treat non-infectious causes (eye squints, circumcision, hernia, etc).   207 
Both patients and healthy controls – parents on behalf of children - received verbal and 208 
written explanations of the study and signed informed consent forms. Ethical approval was 209 
obtained from the Newcastle and North Tyneside Local Research Ethics Committee. 210 
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9 
Generation of monocyte-derived dendritic cells from patient blood 211 
Peripheral blood mononuclear cells were isolated from patient blood by density 212 
centrifugation over a layer of lymphoprep (Axis-Shield, Oslo, Norway).  CD14-positive cells 213 
were then purified by magnetic separation on an LS column following labelling of the cells with 214 
anti-CD14-coated magnetic beads (Miltenyi Biotec, Bergisch Gladbach, Germany), which 215 
regularly yielded a purity of 94-98% CD14+ cells, excluding T cell contamination. Purified 216 
monocytes were then seeded into a 24-well plate at 0.75x10
6
 monocytes per well in 1ml total 217 
volume of RF10 media. RF10 media consists of RPMI-1640 (BioWhittaker, Lonza Wokingham, 218 
UK) media supplemented with 10% fetal calf serum (PAA Laboratories, Pasching, Austria), 219 
2mM L-glutamine (Sigma Aldrich, St. Louis, MO), and 1% Penicillin-Streptomycin (Gibco, 220 
Carlsbad, CA).  50ng/ml IL-4 and GM-CSF (Immunotools, Friesoythe, Germany) were added to 221 
each well.  Cells were incubated at 37
o
C with 5% CO2.  On day 3, the addition of 50ng/ml IL-4 222 
and GM-CSF to the wells was repeated. 223 
 224 
Dendritic cell maturation 225 
On day 6 of the DC culture, immature dendritic cells were divided into 4 groups and 226 
activated as follows: no treatment (unstimulated); addition of 1:10,000 final dilution of heat-227 
killed Candida albicans hyphae (ATCC #18804, Manassas, VA); 1µg/ml of lipopolysaccharide 228 
(LPS) (Invivogen, San Diego, CA); 10ng/ml of the purified TLR2/6 ligand, MALP-2 (Apotech, 229 
Epalinges, Switzerland).  Cells or cytokines were harvested for analysis after 24h on day 7. 230 
 231 
Flow cytometry 232 
To assess Toll-like receptor expression on monocytes and quantitate DC subsets in the 233 
blood, antibodies to various cell surface molecules and appropriate isotype controls were added 234 
directly to 40µl aliquots of patient blood.  After a 15 minute incubation at room temperature, red 235 
blood cells were lysed by the addition of 1.5ml of BD FacsLyse Buffer (BD Biosciences, San 236 
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10 
Jose, CA, USA) for 10 minutes.  Samples were then washed 2x in 1ml FACS Wash (PBS + 237 
0.1% BSA) and fixed in 1% paraformaldehyde (Sigma-Aldrich, St. Louis, MO, USA).  The 238 
following antibodies were used to stain cells in whole blood: CD11c-FITC, CD3-PE, CD14-239 
FITC, CD14-PE（ImmunoTools, Friesoythe, Germany, CD19-PE, HLA-DR-PerCP (BD 240 
Biosciences, San Jose, CA, USA), CD123-APC (Miltenyi Biotec, Bergisch Gladbach, Germany), 241 
TLR1-PE, TLR2-PE, TLR4-PE (eBioscience, San Diego, California, USA), TLR6-FITC 242 
(IMGENEX, San Diego, California, USA), IgG1-FITC, IgG1-PE, IgG2a-PE (BD Pharmingen, 243 
San Jose, CA, USA) and appropriate isotype controls (BD Biosciences, San Jose, CA). DCs were 244 
identified as HLA-DR / CD11c (myDCs) or CD123 (pDCs) positive, CD3, CD14, CD19 245 
negative cells. CD14+ cells were stained for TLR expression.  246 
All stained cells were acquired using a FACScan (BD Biosciences, San Jose, CA) 247 
equipped with a 488nm laser and a 633nm laser upgrade.  Acquired events were analyzed using 248 
FlowJo software (Tree Star, Inc., Ashland, OR).   249 
 250 
Real-time PCR  251 
RNA was purified using the RNeasy Mini kit, including an on-column DNAse I digestion 252 
(Qiagen, Crawley, UK). cDNA was synthesized from 0.4µg of total RNA, using Superscript II 253 
reverse transcriptase and random hexamers in a total volume of 20 µl according to the 254 
manufacturer’s instructions (Invitrogen). cDNA was stored at -20°C until used in downstream 255 
real-time polymerase chain reaction (PCR). Oligonucleotide primers were designed using 256 
Primer3 as part of the Universal Probelibrary package (Roche).  257 
Primers for PRRs were as follows: TLR1 forward 5’-258 
CCTAGCAGTTATCACAAGCTCAAA-3’, reverse 5’- TCTTTTCCTTGGGCCAT TC-3’; 259 
TLR2 forward 5’- CGTTCTCTCAGGTGACTGCTC-3’, reverse 5’- CCTTT 260 
GGATCCTGCTTGC -3’; TLR3 forward 5’- AGTTGTCATCGAATCAAATTAAA GAG -3’, 261 
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11 
reverse 5’- AATCTTCCAATTGCGTGAAAA -3’; TLR5 forward 5’- GA 262 
CACAATCTCGGCTGACTG -3’, reverse 5’- GCCAGGAACATGAACATCAA -3’;  263 
TLR6 forward 5’- TGAGGTTAGCCTGCCAGTTAG -3’, reverse 5’- GCATTTACT 264 
CAAAAGAGACTGTTTCA -3’; TLR7 forward 5’- GCTAGACTGTCTCAAAAGA 265 
ACAAAAA -3’, reverse 5’- GCCCACACTCAATCTGCAC -3’; TLR8 forward 5’- 266 
GGGAGAATGAAGGAGTCATCTTT -3’, reverse 5’- TCAGCATTGACGACTGAA GG -3’; 267 
TLR9 forward 5’- TGTGAAGCATCCTTCCCTGT -3’, reverse 5’- 268 
GAGAGACAGCGGGTGCAG -3’; TLR10 forward 5’- TCTCAGCCCATCTCTGG ATT -3’, 269 
reverse 5’- TGGATTTCTTCCCGCATTTA -3’; Dectin1 forward 5’- CTTT 270 
CTCGGCCCCAGACT -3’, reverse 5’- TTGGGTAGCTGTGGTTCTGA -3’; Syk forward 5’- 271 
CGTCCACAACTTCCAGGTTC -3’, reverse 5’- AGGGGAGGACTTTC TGTGG -3’; Dectin2 272 
forward 5’- TTCAAGTCTCACCTGCTTCAGT -3’, reverse 5’- TCCAAGAAGCTGGGCAAC 273 
-3’.  274 
Relative quantitation of genes was performed using the ABI Prism 7900HT sequence 275 
detection system (Applied Biosystems, Foster City, CA, USA). TLR1,2,3,5,6,7,8,9,10, Dectin1, 276 
Syk and Dectin2  expressions  were determined using SYBR Green (Takara Bio Inc., Shiga, 277 
Japan) in accordance with the manufacturer’s suggested protocol. PCR mixtures contained 50% 278 
Sybr-Green PCR mix (Takara Bio Inc.)（50 nM (except 500nM for TLR3 and 10) of each primer 279 
and 3.2ng cDNA in a total volume of 20 µl. Conditions for PCR were as follows: 10 seconds at 280 
95°C, then 40 cycles each consisting of 5 seconds at 95°C and 30 seconds at 60°C, followed by a 281 
dissociation plot. To confirm that the amplification product was a single amplicon, products were 282 
analysed by agarose gel electrophoresis.  283 
TLR4 and CARD9 expression was determined using TaqMan Gene Expression Assays. 284 
PCR mixtures contained 50% TaqMan mastermix reagents (Sigma-Aldrich, St. Louis, MO, 285 
USA), 1µl of primer and probe mixture (assay ID Hs00152939_m1 for TLR4, Hs00364485_m1 286 
for CARD9, Applied Biosystems, Foster City, CA, USA), 1µl H2O and 3.2ng cDNA in a total 287 
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12 
volume of 20 µl.  Conditions for PCR were as follows: 2 minutes at 50°C, 10 minutes at 95°C, 288 
then following 40 cycles each consisting of 15 seconds at 95°C and 1 minute at 60°C. . 289 
The GAPDH gene was used as an endogenous control to normalise for differences in the 290 
amount of total RNA present in each sample; GAPDH TaqMan primers and probe were 291 
purchased from Applied Biosystems. TaqMan mastermix reagents (Sigma-Aldrich, St. Louis, 292 
MO, USA) were used according to the manufacturer’s protocol. Where data are presented, the 2
-
293 
(CT gene – CT GAPDH)
 (2
-∆CT
) calculation was used as an approximate measure of expression to allow 294 
comparison of expression levels between genes.  295 
 296 
Candida albicans 297 
Freeze-dried Candida albicans was purchased from American Type Culture Collection 298 
(#18804, Manassas, VA) and rehydrated according to the supplier’s instructions. Candida 299 
albicans was grown in autoclaved 1x broth (67g/L Yeast Nitrogen Base (YNB) and 10% D-300 
Glucose) at 30
o
C. Candida yeasts were propagated into hyphal forms in RPMI with 10% FCS at 301 
37oC and heat-killed before use in dendritic cell cultures. The concentration of Candida yeasts in 302 
YNB was determined to be 24.5x10
6
 by counting in a haemocytometer (10mg/ml protein 303 
content). Transformation of >98% yeasts into hyphae was confirmed by visual inspection under 304 
the microscope. Dense flasks of hyphae were decanted into newly-purchased sterile glass bottles 305 
and heated in a pressure cooker for 30 minutes at 120
o
C, based on previous titration experiment.  306 
Heat-killed Candida albicans was centrifuged at 400g for 10 minutes, and the supernatant was 307 
removed without disrupting the pellet.  The pelleted material was used in cell cultures at a final 308 
concentration of 1:10,000.   309 
Statistical analysis 310 
Results were analysed separately for groups of patients with a confirmed AIRE gene mutation 311 
(APECED), patients without a confirmed AIRE gene mutation (non-APECED) and healthy 312 
controls.  Statistical analysis were performed using the freely available software package R [19]. 313 
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13 
For each gene, we fitted a random effects model with treatment type, subgroups, age and patient 314 
as covariates. Interactions between treatment type and subgroups were also considered. Where 315 
necessary we transformed the expression level via a log or an square root transformation. 316 
Variables that were not statistically significant at the 0.05 level (based on the ANOVA results) 317 
were removed and the model was refitted. At each point of model fitting the residuals were 318 
examined to check that our assumptions were valid. To explore individual differences amongst 319 
subgroups and treatments we calculated adjusted p-values to control the family-wise error rate. 320 
Average values are presented as means +/- standard errors of the mean (SEM); level of 321 
significance was set at p<0.05. The graphical network in Figure 4 was calculated using graphical 322 
Gaussian models (GGMs) and shows partial correlations which took into account all available 323 
variables. Inclusion and exclusion of edges was determined using the method described by Drton 324 
and Perlman, 2003 [20]. 325 
Expression analysis and clustering were assessed with the GeneSpring, Agilent 326 
Technologies software. The data analysis for the clusters involved importing the data into 327 
GeneSpring and genes were clustered using a 5 cluster k-means with 100 iterations using a 328 
Pearson correlation for the similarity measure. 329 
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14 
RESULTS 330 
Percentages of monocytes, plasmocytoid and myeloid DC subsets in peripheral blood (ex 331 
vivo) from patients with CMC and controls 332 
In peripheral blood, monocytes, identified as CD14+ cells, showed significantly higher 333 
percentages in APECED and nonAPECED patients compared to controls (Table 1). There was 334 
no significant difference in percentages of myeloid and plasmocytoid DCs between controls, 335 
APECED and nonAPECED patients (Fig 1).  336 
 337 
Expression of TLR2 and TLR6 on monocytes ex-vivo 338 
The percentage and intensity of TLR2 and TLR6 expression was assessed on peripheral 339 
blood monocytes, defined as CD14+ cells. The percentage of TLR2+ CD14+ cells did not differ 340 
between patient groups and controls, but median fluorescence intensity (MFI) was significantly 341 
higher in APECED patients compared to controls and nonAPECED patients. Interestingly, non-342 
APECED patients had a significantly higher frequency of TLR6+CD14+ monocytes compared 343 
to both APECED patients and controls, although the MFI was comparable (Table 1). 344 
 345 
moDC mRNA expression of TLR 1, 4 and 6 (involved in protection against Candida) 346 
All groups had similar TLR1 mRNA expression in immature DCs. Healthy controls 347 
significantly downregulated TLR1 expression in response to all stimuli, in particular to LPS (Fig 348 
2A). As opposed to this, APECED and non-APECED CMC patients failed to downregulate 349 
TLR1 mRNA expression following stimulation with either CH or TLR2/6 ligand, although they 350 
did respond to LPS (Fig 2A). APECED and nonAPECED patients expressed lower levels of 351 
TLR4 mRNA in immature DCs compared to controls albeit not significantly. As opposed to 352 
controls where TLR4 was vigorously downregulated to all stimuli used, non-APECED patients 353 
did not respond to CH, while APECED patients did not respond to either CH or TLR2/6 ligand. 354 
They did however, respond to LPS (Fig 2B). An identical pattern to TLR1 was seen for TLR6 355 
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15 
(Fig 2C), i.e. controls downregulated mRNA expression in response to all stimuli used while 356 
APECED and non-APECED patients responded only to LPS.  357 
 In summary, healthy controls significantly downregulated TLR1, 4, and 6 mRNA 358 
expression in response to all stimuli used. As opposed to this, APECED and non-APECED CMC 359 
patients failed to downregulate TLR 1, 4, and 6 expression following stimulation with CH and / 360 
or TLR2/6 ligand, although the response to LPS stimulation was similar to controls. 361 
 362 
moDC mRNA expression of TLR 2 (with controversial role in protection against Candida) 363 
TLR2 mRNA in immature moDCs was readily detectable and comparable in both patient 364 
groups and controls. Interestingly, upon stimulation / maturation, healthy controls  365 
downregulated TLR2 expression only in response to LPS. CMC patients, both APECED and 366 
non-APECED failed to downregulate TLR2 in response to any of the stimuli (data not shown).  367 
 368 
moDC mRNA expression of TLR 3, 5 and 10 (not known to have a role in protection 369 
against Candida) 370 
TLR3 and TLR10 mRNA was detectable, but did not change in response to any of the 371 
stimuli used (data not shown). An unusual finding was the downregulation of TLR5 mRNA 372 
expression in healthy controls in response to all stimuli - CH, TLR2/6 ligand and LPS. Non-373 
APECED patients also responded to all 3 stimuli while APECED patients did not respond to any 374 
(data not shown).  375 
  376 
Dectin-1, Syk and CARD9 moDC mRNA expression 377 
Immature moDCs expressed readily detectable and comparable levels of mRNA in 378 
patients and controls. Dectin-1 mRNA levels in moDCs did not change in either healthy controls 379 
or CMC patients (both APECED and non-APECED) in response to CH or TLR2/6-ligand 380 
stimulation, but decreased significantly following LPS stimulation (Fig 3A). In contrast, healthy 381 
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16 
controls responded by decreasing Syk mRNA expression in response to all 3 stimuli. As 382 
opposed to this APECED patients only responded to LPS stimulation but not to either CH or 383 
TLR2/6-ligand. Non-APECED patients did not respond to TLR2/6-ligand stimulation but 384 
decreased their mRNA expression following stimulation with both CH and LPS (Fig 3B). 385 
Interestingly, healthy controls did not alter CARD9 expression except in response to LPS, as was 386 
also the case with APECED and non-APECED patients (Fig 3C). An additional finding was that 387 
in healthy controls, the levels of Dectin-1 mRNA increased significantly with age which was not 388 
seen in either APECED or non-APECED CMC patients (data not shown)  389 
 390 
moDCs TLR7, 8, 9 and Dectin-2 mRNA expression 391 
mRNA levels of TLR 7, 8, 9 and Dectin-2 were undetectable or borderline low in both 392 
immature and mature moDCs with all stimuli used.  393 
A summary of changes in mRNA PRR expression following stimulation in APECED, 394 
non-APECED patients and controls is given in Table 2.  395 
Based on the above results and data on cytokine production by these same moDCs 396 
previously published [15], we present a graphical dependency network (Fig 4) demonstrating the 397 
interactions between cytokine production and PRR expression by stimulated moDCs from CMC 398 
patients and healthy controls.  The network demonstrates the interdependence of cytokines and 399 
PRRs relevant for protective immunity to Candida, and highlights differences between CMC 400 
patients and healthy controls. It demonstrates that CMC patients lack the interaction found in 401 
healthy controls between TLR1, TLR4, TLR6 and Th1 cytokines IL-12/IL-23/IFNg/IL-2,  but 402 
have an interdependence of Dectin-1/Syk/CARD9 that is not evident in healthy controls. These 403 
findings suggest that the immune defect in CMC patients may lie in the interaction of TLR 1/4/6 404 
and Th1 cytokine production, which may be compensated by the Dectin-Syk-CARD9 pathway in 405 
CMC patients. 406 
 407 
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17 
Clustering analysis of PRRS and cytokines levels which were reported previously [15] 408 
showed associations for TLR1, 4, 6, Dectin-1, Syk, CARD9 (Set1), TLR2, 5, 10, interleukin 409 
(IL)-2, IL-10, IL-13 (Set2) and TLR7, 8, IL-6, IL-12, IL-23, IL27 (Set3), which did not differ 410 
significantly between healthy controls and patients (data not shown). 411 
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18 
DISCUSSION 412 
Candida infections range from benign, commensal colonisations of skin and mucous membranes 413 
in normal individuals to persistent, debilitating mucocutaneous infections (as seen in CMC 414 
patients) or life-threatening systemic candidemias with a significant mortality of over 30% in 415 
immunocompromised patients [16]. The role of the innate immune system in the protection 416 
against Candida has long been recognised, but was thought to be limited to first line 417 
phagocytosis and killing. More recently, it has become clear that the innate immune system not 418 
only distinguishes between various microorganisms, but through interactions with DCs, initiates 419 
and guides subsequent adaptive immune responses [21]. The crucial task of recognising invading 420 
pathogens and activating host responses is delivered by PRRs which recognise PAMPs on the 421 
microbes cell wall [3].   422 
 Most components of the fungal cell wall are not found in mammals and are thus ideal 423 
PAMPS for recognition of non-self. The core of the Candida albicans cell wall is made of 424 
polysaccharide fibrils composed of β-glucan  and chitin. The outer layer is made of proteins that 425 
are glycosylated with mannose - coined mannan or mannoprotein. These structures differ 426 
between fungi and are the major structures recognised my PRRs such as TLRs and CTLs [22]. 427 
 The role of TLRs in defence was first recognised in the Drosophila model of 428 
fungal infection [23]. Subsequent studies demonstrated that ligand recognition by TLRs induces 429 
differential activation of signalling cascades and leads to cytokine and chemokine production 430 
[24]. TLR2 and TLR6 were the first TLRs shown to be involved in recognition of a fungal 431 
structure – zymosan, derived from Saccharomyces cervisiae [17] and the adaptor MyD88, 432 
shared by all TLRs (except TLR3), was repeatedly confirmed to be crucial for fungal defence in 433 
mice.  At least 4 TLRs (TLR2, TLR2, TLR4, TLR6) are involved in triggering cytokine 434 
production by Candida albicans. Recognition of Candida at the cellular level is mediated by 435 
TLRs and CTL receptors [25]. TLR4 induces mainly pro-inflammatory signals through the 436 
MyD88 dependent pathway, leading to activation of nuclear factor (NF)-κB, mitogen-activated 437 
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19 
protein (MAP)-kinases and interferon-releasing factor 3 (IRF3), stimulating Th1 responses 438 
through production of IL-12, IFNγ, tumour necrosis factor (TNFα) and type 1 IFNs, resulting in 439 
efficient elimination of Candida infection. In contrast, binding of Candida to TLR2 leads to 440 
production of transforming growth factor (TGF)β and IL-10, leading to tolerance, 441 
immunosuppresion and generation of T-regulatory cells [26]. However, TLR2 is also able to 442 
associate with Dectin-1 in the induction of pro-inflammatory responses [27]. In CMC patients, 443 
we previously demonstrated low IL-12 and very high IL-10 and IL-6 production by PBMCs [28], 444 
with low IL-23 and high IL-6 responses by moDCs [15]. The results in our current study show 445 
normal expression of TLRs and CTLs on immature moDCs but inadequate downregulation of 446 
TLR1, 4 and 6, suggesting defects in signalling pathways downstream of these receptors. More 447 
recent data suggests TLR9 can recognise fungal  DNA, but the importance of this in fungal 448 
defence is still not clear [3]. Whether any of these pathways is directly involved or impacts on 449 
other signalling pathways such as Dectin-1 is unclear, as would be suggested by our ongoing 450 
studies which have demonstrated markedly reduced IL-17 production in non-APECED (but not 451 
APECED) patients [29]. AIRE gene mutations hav  also been shown to critically downregulate 452 
immunological pathways in DCs from APECED patients [30], suggesting that this mechanism 453 
may be involved in impaired immune responses to Candida. However, AIRE gene mutations 454 
may affect DC function in alternative ways, such as increasing antigen-presentation to T cells 455 
[31] or interfering with T-regulatory cell induction / function, as has been demonstrated [32, 33]. 456 
Recently, patients with MyD88 deficiency were reported to suffer with pyogenic 457 
infections, including invasive pneumococcal diseases, but were otherwise healthy. Our patients 458 
with CMC did not suffer with severe, life-threatening infections caused by pyogenic bacteria, 459 
although a previous report in children with CMC demonstrated a high incidence of bacterial 460 
infection and mortality from non-Candida infections [34]. 461 
Mannose-binding lectin (MBL) is a soluble C-type lectin receptor that binds Candida and 462 
other microorganisms, promoting complement deposition. Low levels of MBL in humans 463 
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20 
predispose to infections, althought MBL-deficient mice do not show increased susceptibility to 464 
infections with Candida [35]. There is some evidence for a role of MBL in recurrent 465 
vulvovaginal candidiasis [36], but its’ importance – if any – in CMC is not clear. 466 
In this study, we show for the first time that patients with CMC, both APECED and non-467 
APECED have normal frequencies of both myeloid and plasmocytoid DC subsets in peripheral 468 
blood, indicating that a major lack of these cells is not responsible for their increased 469 
susceptibility to Candida infections. The higher frequency of blood monocytes in CMC patients 470 
(both APECED and nonAPECED) might be due to ongoing Candida-induced inflammation. 471 
Almost all monocytes in both patients and controls expressed TLR2, which was upregulated in 472 
APECED patients. Interestingly, TLR6 was expressed on almost all monocytes in non-APECED 473 
patients but not in the other groups. These findings argue against an intrinsic defect in TLR2 and 474 
TLR6 expression on monocytes in CMC patients as and underlying cause of their increased 475 
susceptibility to Candida infections.  476 
In our study, TLR1, 4, 6, 2 and TLR5 mRNA was expressed in immature moDCs in all 477 
patients and controls and the level of expression did not differ significantly between groups. This 478 
is the first study to report that expression of these TLRs in immature myeloid DCs of APECED 479 
and non-APECED CMC patients is normal.  480 
Previous studies have demonstrated that when moDCs are induced to mature by 481 
stimulation with pathogens or pathogen PAMPS, levels of TLR mRNA decrease or disappear, as 482 
opposed to macrophages and monocytes [37] where TLR mRNA increases. In healthy 483 
individuals, decreased mRNA expression was reported already 2h after stimulation but was most 484 
obvious after 24h ([38], suggesting that decreased levels of TLR mRNA are consistent with 485 
normal DC maturation dynamics. In our study, we found that healthy controls downregulated 486 
TLR1, 4, 6 and 5 in response to all stimuli used (CH, TLR2/6 ligand and LPS). In contrast 487 
APECED patients responded only to LPS and did not downregulate TLR1, 4, 6 and 5 mRNA  488 
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21 
expression when stimulated with either CH or TLR2/6 ligand. Non-APECED patients similarly 489 
failed to downregulate TLR1 and TLR6, but they did downregulate TLR4 in response to TLR2/6 490 
ligand (but not CH) and downregulated TLR5 in response to all stimuli, similarly to controls. On 491 
the other hand TLR2 expression in healthy controls changed only in response to LPS but no 492 
change was seen following CH or TLR2/6 ligand stimulation. In APECED and non-APECED 493 
patients, TLR2 mRNA expression did not change in response to any of the stimuli used. In 494 
summary, when stimulated with Candida and Candida-like stimuli, APECED patients did not 495 
downregulate any of the TLRs known to be involved in anti-Candida responses (TLR1, 4, 6, 2), 496 
while non-APECED patients downregulated only TLR4 in response to TLR2/6 ligand. These 497 
findings suggest that moDCs in both APECED and non-APECED patients have normal patterns 498 
of mRNA TLR expression in immature DCs, but that progression to maturation is altered, 499 
particularly in response to Candida and Candida-like stimuli, suggesting impaired maturation of 500 
DCs in these patients.  501 
The results reported in this paper were part of a larger study which included assessment 502 
of a range of cytokines produced (IL-12p70, IL-23, IFNγ, IL-2, TNFα, IL-6, TGFβ, IL-10, IL-5, 503 
IL-13) as well as cell-surface maturation marker expression (CD83, CD86, HLA-DR) by the 504 
same dendritic cells on which PRR expression was assessed, recently published [15]. These 505 
results demonstrated that in both APECED and non-APECED CMC patients, DC function was 506 
impaired as evidenced by altered cytokine expression profiles and DC maturation/activation: 1) 507 
both groups over-produce IL-2, IFNγ, TNFα, IL-13 and demonstrated impaired DC maturation. 508 
2) Only non-APECED patients showed markedly decreased Candida-stimulated production of 509 
IL-23 and markedly increased production of IL-6, suggesting impairment of the IL-6/IL-23/Th17 510 
axis. 3) In contrast, only APECED patients showed DC hyper-activation, which may underlie 511 
altered T-cell responsiveness, autoimmunity and impaired response to Candida.  The altered 512 
cytokine production may well be linked to the altered PRRs downregulation in maturing DCs in 513 
particular TLR 1, 4 and 6 which are known to be involved in Candida responses. 514 
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22 
The interdependence of cytokines and PRRs relevant for protective immunity to 515 
Candida in CMC patients and healthy controls is also demonstrated in Fig 4. Amazingly, it 516 
shows that CMC patients lack the interaction found in healthy controls between TLR1/4/ 6 and 517 
Th1 cytokines IL-12/IL-23/IFNg/IL-2, but demonstrate an interdependence of Dectin-518 
1/Syk/CARD9 that is not evident in healthy controls, possibly as a compensatory mechanism. 519 
An unexpected and unexplained finding is the downregulation of TLR5 mRNA in both 520 
healthy controls and non-APECED patients to CH, TLR2/6, suggesting that TLR5 may be 521 
involved in recognition of Candida PRRs, which has not been observed previously. 522 
Alternatively, “cross-talk” among TLRs and their ligands can be involved, where microbial 523 
PAMPs are able to affect mRNA and protein expression of different TLRs. It was reported that 524 
in addition to flagellin which is the known TLR5 ligand, unrelated PAMPs such as peptidogycan 525 
can exert a general stimulatory activity on TLR5 expression [39]. 526 
Dectin-1, Syk and CARD9 mRNA levels in immature moDCs were readily detectable in 527 
all groups. Both CMC patients and healthy controls showed a robust downregulation in response 528 
to LPS, but less so to Candida or TLR2/6 ligand stimulation, where patients actually responded 529 
more robustly than controls. This was surprising given the important role of the Dectin-1, Syk 530 
and CARD9 pathway in fungal immune responses [40]. A possible explanation is the lack of β-531 
glucan on the surface of Candida hyphae as opposed to yeasts, as previously reported [27] which 532 
is necessary for the engagement of Dectin-1.  Dectin-1 binds β-glucans on the Candida cell wall 533 
and activates the Syk-CARD9 signalling pathway [41],  leading to production of IL-17, which is 534 
increasingly thought to be of major importance in protection against Candida infection  [9]. 535 
Recently, a homozygous mutation in the CARD9 gene was reported in a family where patients 536 
suffered with recurrent oral and vaginal candidiasis, but in contrast to classical CMC, suffered 537 
with other fungal (dermatophyte) infections as well [42]. The relevance of this finding for 538 
patients with classical CMC (which were investigated in this study) is under investigation, 539 
although our results demonstrate that both APECED and non-APECED CMC patients responded 540 
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23 
to Candida by downregulating CARD9. Interestingly, the network connectivity analysis in our 541 
study (Fig 4) actually suggests that the Dectin-1-Syk-CARD9 pathway was of greater relevance 542 
for Candida responses in our CMC patients than in healthy controls.  543 
 In summary, we have demonstrated that CMC patients, with or without APECED do not 544 
lack plasmocytoid or myeloid dendritic cells in blood, nor do they harbour defects of monocyte-545 
TLR expression, relevant for anti-Candida responses. In immature moDCs, levels of mRNA 546 
expression for all PRRs involved in anti-Candida responses (TLR1, 2, 4, 6, Dectin-1, Syk, 547 
CARD9) were comparable to normal controls, strongly suggesting that defects in PRR 548 
expression are unlikely to be responsible for the increased susceptibility to Candida infections in 549 
these patients.  However, both groups of CMC patients (APECED patients in particular), fail to 550 
downregulate PRR mRNA expression in response to Candida stimulation, implying defective 551 
DC maturation, possibly involving defective TLR and/or CTL signalling, which could be 552 
responsible for inadequate Candida handling seen in these patients. Further investigation of TLR 553 
and CTL signalling pathways will elucidate putative defects in CMC patients which may 554 
underlie their inability to clear Candida. 555 
 556 
 557 
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27 
Table 1. Whole blood myeloid (my) and plasmocytoid (p) dendritic cell (DC) percentages 670 
and expression of TLR2 and TLR6 on CD14+ monocytes. 671 
 APECED Non- 
APECED 
Controls APECED Non- 
APECED 
Controls 
 Percentage - % Median Fluorescence Intensity - 
MFI 
CD14+ 7.6** 
(±0.4) 
8.0 ** 
 (±0.7) 
6.3 
(±0.6) 
NA NA NA 
TLR2 97  
(±1.5) 
95  
(±1.3) 
93  
(±2.4) 
193*  
(±21) 
160  
(±9) 
142 
(±19) 
TLR6 83  
(±6) 
96**  
(±1) 
74  
(±8) 
27  
(±8) 
16  
(±2) 
14  
(±2) 
myDCs 0.54  
(±011) 
0.46 
(±0.01) 
0.52 
(±0.06) 
pDCs 0.10 
(±0.02) 
0.07 
(±0.01) 
0.10 
(±0.01) 
DCs in whole blood were identified as HLA-DR positive, CD11c (myDCs) or CD123 (pDCs) 672 
positive, CD3, CD14, CD19 negative cells. Monocytes, identified as CD14+ cells were stained 673 
for TLR expression. Numbers are Means ±SEM. NA = not applicable; *p=0.03, ** = p=0.02;  674 
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28 
Table 2. Summary of TRL/PRR mRNA expression in APECED, non-APECED patients 675 
and healthy controls 676 
 APECED Non- 
APECED 
Controls APECED Non- 
APECED 
Controls APECED Non- 
APECED 
Controls 
 Candida hyphae TLR 2/6 ligand LPS 
TLR1   → → ↓ → → ↓ ↓ ↓ ↓ 
TLR4 → → ↓ → ↓ ↓ ↓ ↓ ↓ 
TLR6 → → ↓ → → ↓ ↓ ↓ ↓ 
TLR2 → → → → → → → → ↓ 
 
Dectin-1 → → → → → → ↓ ↓ ↓ 
Syk → ↓ ↓ → → ↓ ↓ → ↓ 
CARD9 → → → → ↓ → ↓ ↓ ↓ 
 
TLR5 → ↓ ↓ → ↓ ↓ → ↓ ↓ 
TLR3 → → → → → → → → → 
TLR10 → → → → → → → → → 
Immature mDC were stimulated with Candida albicans hyphae, a specific TLR2/6 ligand or 677 
LPS.  After 24h, RNA was extracted from mDCs and processed for mRNA PCR analysis.  678 
Arrows indicate statistically significant increases (↑), decreases (↓) or no changes (→ ) of 679 
mRNA expression  compared to levels in unstimulated mDCs. mRNA for TLR7/8/9 and Dectin-680 
2 was undetectable (not shown). 681 
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29 
Figure legends 682 
Figure 1.  Representative flow-cytometry plots of whole blood stains. Whole blood was 683 
stained directly with antibodies to various cell surface molecules and appropriate isotype 684 
controls, lysed, washed and fixed as described. Cells were acquired using a FACScan (BD 685 
Biosciences, San Jose, CA) and analysed using FlowJo software (Tree Star, Inc., Ashland, OR).  686 
A & B: Myeloid (my) and plasmocytoid (p)DCs flow cytometry dot-plots ex-vivo. *myDCs 687 
were identified as HLA-DR/CD11c positive, CD3/CD14/CD19 negative cells (1.31% of total 688 
lymphocyte population and 15.8% of CD11c/HLA-DR positive cells on graph shown). **pDCs 689 
were identified as CD123/HLA-DR positive, CD3/CD14/CD19 negative cells (0.25% of total 690 
lymphocyte polulation and 3.01% of CD123/HLA-DR positive cells on graph shown). C & D: 691 
Flow-cytometry histograms of frequency (%) and median fluorescence intensity (MFI) of 692 
TLR2+ or TLR6+ monocytes in peripheral blood. CD14+ cells were stained for TLR 693 
expression. (92% CD14/TLR2 positive and 79% CD14/TLR6 positive on graphs shown). 694 
Negative peaks represent appropriate isotype controls.   695 
 696 
Figure 2. mRNA expression of TLR 1, 4, and 6 in moDCs from CMC patients with or 697 
without APECED and controls following stimulation with CH, TLR2/6 ligand and LPS 698 
(means +/- SEM). Immature moDCs from patients and controls were either left unstimulated or 699 
treated with Candida albicans hyphae, a specific TLR2/6 ligand or LPS. Immature moDCs from 700 
CMC patients demonstrate normal mRNA expression whereas downregulation after stimulation 701 
with CH and TLR2/6 is impaired. 702 
 703 
Figure3. mRNA expression of Dectin-1, Syk and CARD9 in moDCs from CMC patients 704 
with or without APECED and controls following stimulation with CH, TLR2/6 ligand and 705 
LPS (means +/- SEM). Immature moDCs from patients and controls were either left 706 
unstimulated or treated with Candida albicans hyphae, a specific TLR2/6 ligand or LPS. 707 
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30 
Immature moDCs from both CMC patients and controls have detectable mRNA expression 708 
whereas downregulation after stimulation with CH and TLR2/6 is seen only with Syk. 709 
  710 
Figure 4. Graphical dependency network describing interactions between cytokine 711 
production and PRR expression on moDCs from CMC patients and healthy controls, 712 
relevant for protective immunity against Candida.  The graphical network was calculated 713 
using graphical Gaussian models (GGMs). Each line indicates significant partial correlations 714 
between genes. Black lines denote connections on networks for both CMC patients and healthy 715 
controls. Red lines denote connections on network for healthy controls only. Blue lines denote 716 
connections on network for CMC patients only. The network shows that CMC patients lack the 717 
interactions found in healthy controls between TLR1, TLR4, TLR6 and Th1 cytokines IL-12/IL-718 
23/IFNg/IL-2 (marked in red), but intriguingly demonstrate an interdependence of Dectin-719 
1/Syk/CARD9 (marked in blue) that is not evident in healthy controls.  720 
 721 
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3 
SUMMARY 67 
 68 
Patients with Chronic Mucocutaneous Candidiasis (CMC) have an unknown primary immune 69 
defect and are unable to clear infections with the yeast Candida. CMC includes patients with 70 
AIRE gene mutations who have Autoimmune PolyEndocrinopathy Candidiasis Ectodermal 71 
Dystrophy (APECED), and patients without known mutations. CMC patients have dysregulated 72 
cytokine production, suggesting that defective expression of pattern recognition receptors 73 
(PRRs) may underlie disease pathogenesis. In 29 patients with CMC (13 with APECED) and 74 
controls, we assessed dendritic cell (DC) subsets and monocyte Toll-like receptor (TLR) 75 
expression in blood. We generated and stimulated monocyte-derived (mo)DCs with Candida 76 
albicans, TLR2/6- ligand and lipopolysaccharide and assessed PRR mRNA expression by PCR 77 
(TLR1-10, Dectin-1 & 2, Syk and CARD9) in immature and mature moDCs. We demonstrate 78 
for the first time that CMC patients, with or without APECED have normal blood levels of 79 
plasmocytoid and myeloid DCs and monocyte TLR2 / TLR6 expression. We showed that in 80 
immature moDCs, expression levels of all PRRs involved in anti-Candida responses (TLR1, 2, 81 
4, 6, Dectin-1, Syk, CARD9) were comparable to controls, implying that defects in PRR 82 
expression are not responsible for the increased susceptibility to Candida infections seen in 83 
CMC patients.  However, as opposed to healthy controls, both groups of CMC patients failed to 84 
downregulate PRR mRNA expression in response to Candida, consistent with defective DC 85 
maturation, as we recently reported. Thus, impaired DC maturation and consequent altered 86 
regulation of PRR signalling pathways rather than defects in PRR expression may be responsible 87 
for inadequate Candida handling in CMC patients. 88 
 89 
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4 
INTRODUCTION 90 
Pattern recognition receptors (PRRs) on cells of the innate immune system recognise core 91 
structures specific to microorganisms (pathogen associated molecular patterns or PAMPS) that 92 
are alien to mammals [1], [2]. Toll-like receptors (TLR), particularly TLR 1, 2, 4 and 6 and C-93 
type lectin receptors (CLRs) such as Dectin-1 and 2, mannose receptor (MR) and dendritic cell-94 
specific intercellular adhesion molecule-3 (ICAM-3)-grabbing non-integrin (DC-SIGN) are 95 
known to be important PRRs in fungal recognition, initiating immune responses to these 96 
pathogens [3]. More recently, complex interactions and collaboration of these receptors through 97 
formation of heterodimers have been demonstrated to modulate immune responses to different 98 
fungi [4]. 99 
In mice, activation of TLR4 initiates interleukin (IL)-12 production by dendritic cells 100 
(DCs) generating a protective Th1 response. In contrast, activation of TLR2 mediates a non-101 
protective Th2 response via IL-10 production and generation of T regulatory cells [5]. TLR1 and 102 
TLR6 form heterodimers with TLR2 modulating the Th1/Th2 balance in response to fungi [6], 103 
while Dectin-1 synergizes with TLR2 and TLR4 for cytokine production [7]. However, humans 104 
with inborn errors of the IL-12/IFNγ pathway do not show increased susceptibility to Candida or 105 
other fungal infections [8], suggesting that this pathway might not have the same importance in 106 
fungal defences in humans as in mice. Recent evidence suggests that the Th-17 pathway is 107 
crucially involved in immune response to fungi [9]. Dectin-1 signalling through a non-TLR 108 
signalling pathway that involves the spleen tyrosine kinase (Syk) and adaptor caspase 109 
recruitment domain (CARD) 9 [10], primes dendritic cells to “instruct” differentiation of CD4+ 110 
IL-17 producing effector T cells, demonstrating a direct link between the innate and adaptive 111 
immune system [11] in generating protective fungal responses.  112 
Chronic Mucocutaneous Candidiasis (CMC) is a primary immunodeficiency disorder 113 
(PID) with selective susceptibility to recurring and/or persistent, debilitating infections with the 114 
yeast Candida [12] and includes several subtypes. The APECED syndrome (Autoimmune 115 
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5 
PolyEndocrinopathy Candidiasis Ectodermal Dystrophy), also known as APS1 (Autoimmune 116 
PolyEndocrinopathy Type 1) is associated with organ-specific autoimmune involvement of 117 
particularly the endocrine glands and an underlying mutation of the AIRE gene (Online 118 
Mendelian Inheritance in Man - OMIM 240300). Other subgroups of CMC include patients with 119 
associated thyroid disease but no other autoimmunity (OMIM 606415), isolated CMC with 120 
various modes of inheritance (OMIM 11458, OMIM 212050) and sporadic CMC. In these CMC 121 
patients the diagnosis remains clinical, given that a genetic or biochemical marker is not yet 122 
available.   123 
Very little is known about the immune defect underlying increased susceptibility to 124 
Candida infections in CMC patients. Previously, we demonstrated dysregulated cytokine 125 
production in response to Candida [12] suggesting that the immune defect might be at the level 126 
of orchestrating appropriate cytokine responses, rather than the effector T cell level itself.  127 
Our assumption that defects of PRRs, which can recognise moeities from many different 128 
organisms, could specifically cause an immune defect against Candidas is based on the recent 129 
recognition of similar scenarios underlying non-conventional primary immune deficiencies 130 
(PIDs), defined as a selective susceptibility to a single weakly pathogenic or opportunistic 131 
organism. Surprisingly, in these PIDs, a predisposition to a single type of infection is caused by 132 
immune defects affecting pathways central to the immune response. Examples include disorders 133 
of the interleukin (IL)-12/interferon (IFN)γ circuit resulting in selective susceptibility to 134 
infections with mycobacteria and Salmonella; defects in the TLR3  pathway resulting in selective 135 
predisposition to Herpes Simplex Infection; MyD88 deficiency and susceptibility to pyogenic 136 
bacterial infections. The infectious phenotype that the above disorders confer in humans is much 137 
narrower than those of corresponding mutant mice, suggesting there is much redundancy in 138 
human host defence in nature [13], [14]. In analogy, given that DCs are central initiators of 139 
immune responses, while PRRs and TLRs are known to be involved in production of cytokines 140 
in protective Candida immunity, we hypothesised that reduced DC numbers and/or a defect of 141 
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6 
pattern recognition receptors involved in immune responses to Candida might underlie a 142 
selective susceptibility to this microorganism in patients with CMC.  143 
In CMC patients and age-and-gender matched healthy controls, we investigated the 144 
proportion of DCs and DC subsets in peripheral blood, as well as TLR receptor expression on 145 
blood monocytes; we then isolated monocytes from peripheral blood and cultivated them in-vitro 146 
into monocyte-derived DCs (moDCs), which we stimulated / matured with Candida and other 147 
relevant antigens to assess expression of TLR1-10, Dectin-1 and 2, CARD9 and Syk.. We 148 
demonstrate for the first time that CMC patients, with or without APECED have normal blood 149 
levels of plasmocytoid and myeloid DCs and monocyte TLR2 / TLR6 expression. In immature 150 
moDCs, expression levels of all PRRs involved in anti-Candida responses (TLR1, 2, 4, 6, 151 
Dectin-1, Syk, CARD9) were comparable to controls. However, as opposed to healthy controls, 152 
both groups of CMC patients failed to downregulate PRR mRNA expression in response to 153 
Candida, suggesting that impaired DC maturation and consequently altered regulation of PRR 154 
signalling pathways rather than defects in PR  themselves may be responsible for inadequate 155 
Candida handling in CMC patients.  156 
These results complement our previous report of impaired DC maturation, where 157 
activation and function of these same DCs was investigated in parallel through cytokine 158 
production and cell surface marker expression, which is presented in a separate publication [15].  159 
 160 
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7 
MATERIALS AND METHODS 161 
General conditions 162 
Monocyte-derived DCs were used as representatives of skin and mucosal myeloid-DCs 163 
involved in Candida recognition, because obtaining skin biopsies from CMC patients for purely 164 
research purposes was not deemed acceptable for ethical reasons.  165 
We stimulated moDCs with Candida albicans hyphae (CH) rather than yeasts, as several 166 
studies suggest that hyphae are the invasive morphotype of Candida in clinical infections [16]. 167 
With the aim of investigating putative impaired Candida binding to DCs, we assessed moDC 168 
stimulation with a Toll-like receptor (TLR) ligand 2/6 (MALP2) that selectively engages the 169 
same TLRs that are known to bind Candida and other yeasts [17]. Lipopolysaccharide (LPS) was 170 
used as a “positive” non-Candida control, in order to assess moDC functionality in response to 171 
other potent stimuli. Repeat assessments and inclusion of additional stimuli were limited by the 172 
quantity of blood we could draw from each patient, particularly children. 173 
 174 
Subjects 175 
Patients: We studied 29 patients with CMC, 13 APECED with a confirmed AIRE gene mutation 176 
and 16 non-APECED without. All patients were screened for the two most common AIRE gene 177 
mutations: p.R257X (a nonsense mutation in exon 6) and c.964del13 (a 13bp deletion in exon 8) 178 
(Huch-Laboratory Diagnostics, Helsinki University Hospital, Finland and Northern Molecular 179 
Genetics Service, Institute of Human Genetics, Newcastle Upon Tyne, UK).  Thirteen patients 180 
were found to have an AIRE gene mutation and the APECED syndrome, of which 9 had the 181 
c.964del13 deletion and 4 had the p.R257X mutation. In the remaining 16 non-APECED patients 182 
an AIRE mutation was not detected. None of the patients without the AIRE gene mutation had 183 
any clinical signs suggestive of APECED that would justify investigations of additional AIRE 184 
gene mutations. All patients were screened for autoantibodies to type 1 interferons (IFNs) which 185 
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8 
were recently shown to be highly specific for APECED patients [18]; these autoantibodies were 186 
present in all APECED patients and none of the non-APECED patients and controls.  187 
In the APECED group, 10 patients had affected siblings and 9 in the non-APECED 188 
group, which are all included in this study.  Three patients from the latter group had 189 
hypothyroidism, 2 with thyroid peroxidase antibodies. Not more than 3 patients from any one 190 
family were studied. At the time of sampling, patients did not have any other serious infections, 191 
were not on systemic antibiotic treatment or receiving steroids. All patients suffered from 192 
recurrent mucocutaneous Candida infection (mouth, nails, skin, oesophagus and perineum), but 193 
no other fungal infections including dermatophyte (e.g. tinea corporis) infections. Patients were 194 
screened for systemic autoantibodies (AAbs) including antinuclear factor, smooth muscle, liver-195 
kidney microsomal, mitochondrial and gastric parietal cell antibodies. Systemic AAbs were 196 
found in 4/13 APECED patients and 5/16 non-APECED patients. Organ-specific autoantibodies 197 
and/or endocrinopathy were observed in one or more of the following organs: parathyroid, 198 
thyroid, adrenal cortex, gonads and pancreas. Autoantibodies were evaluated in patients sera 199 
using indirect immunofluorescence on commercial rodent tissue (Euroimmune, Lubeck, 200 
Germany) for systemic autoantibodies and monkey organ tissue (The Binding Sire, Birmingham, 201 
UK) for organ-specific autoantibodes. Endocrinopathy was diagnosed if/when there was clinical 202 
and laboratory evidence of glandular hypofunction. 203 
Controls: 25 age-and-sex matched controls were recruited for the study.  Adults were healthy 204 
laboratory volunteers, while control children were undergoing general anaesthesia for surgery to 205 
treat non-infectious causes (eye squints, circumcision, hernia, etc).   206 
Both patients and healthy controls – parents on behalf of children - received verbal and 207 
written explanations of the study and signed informed consent forms. Ethical approval was 208 
obtained from the Newcastle and North Tyneside Local Research Ethics Committee. 209 
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9 
Generation of monocyte-derived dendritic cells from patient blood 210 
Peripheral blood mononuclear cells were isolated from patient blood by density 211 
centrifugation over a layer of lymphoprep (Axis-Shield, Oslo, Norway).  CD14-positive cells 212 
were then purified by magnetic separation on an LS column following labelling of the cells with 213 
anti-CD14-coated magnetic beads (Miltenyi Biotec, Bergisch Gladbach, Germany), which 214 
regularly yielded a purity of 94-98% CD14+ cells, excluding T cell contamination. Purified 215 
monocytes were then seeded into a 24-well plate at 0.75x10
6
 monocytes per well in 1ml total 216 
volume of RF10 media. RF10 media consists of RPMI-1640 (BioWhittaker, Lonza Wokingham, 217 
UK) media supplemented with 10% fetal calf serum (PAA Laboratories, Pasching, Austria), 218 
2mM L-glutamine (Sigma Aldrich, St. Louis, MO), and 1% Penicillin-Streptomycin (Gibco, 219 
Carlsbad, CA).  50ng/ml IL-4 and GM-CSF (Immunotools, Friesoythe, Germany) were added to 220 
each well.  Cells were incubated at 37
o
C with 5% CO2.  On day 3, the addition of 50ng/ml IL-4 221 
and GM-CSF to the wells was repeated. 222 
 223 
Dendritic cell maturation 224 
On day 6 of the DC culture, immature dendritic cells were divided into 4 groups and 225 
activated as follows: no treatment (unstimulated); addition of 1:10,000 final dilution of heat-226 
killed Candida albicans hyphae (ATCC #18804, Manassas, VA); 1µg/ml of lipopolysaccharide 227 
(LPS) (Invivogen, San Diego, CA); 10ng/ml of the purified TLR2/6 ligand, MALP-2 (Apotech, 228 
Epalinges, Switzerland).  Cells or cytokines were harvested for analysis after 24h on day 7. 229 
 230 
Flow cytometry 231 
To assess Toll-like receptor expression on monocytes and quantitate DC subsets in the 232 
blood, antibodies to various cell surface molecules and appropriate isotype controls were added 233 
directly to 40µl aliquots of patient blood.  After a 15 minute incubation at room temperature, red 234 
blood cells were lysed by the addition of 1.5ml of BD FacsLyse Buffer (BD Biosciences, San 235 
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10 
Jose, CA, USA) for 10 minutes.  Samples were then washed 2x in 1ml FACS Wash (PBS + 236 
0.1% BSA) and fixed in 1% paraformaldehyde (Sigma-Aldrich, St. Louis, MO, USA).  The 237 
following antibodies were used to stain cells in whole blood: CD11c-FITC, CD3-PE, CD14-238 
FITC, CD14-PE（ImmunoTools, Friesoythe, Germany, CD19-PE, HLA-DR-PerCP (BD 239 
Biosciences, San Jose, CA, USA), CD123-APC (Miltenyi Biotec, Bergisch Gladbach, Germany), 240 
TLR1-PE, TLR2-PE, TLR4-PE (eBioscience, San Diego, California, USA), TLR6-FITC 241 
(IMGENEX, San Diego, California, USA), IgG1-FITC, IgG1-PE, IgG2a-PE (BD Pharmingen, 242 
San Jose, CA, USA) and appropriate isotype controls (BD Biosciences, San Jose, CA). DCs were 243 
identified as HLA-DR / CD11c (myDCs) or CD123 (pDCs) positive, CD3, CD14, CD19 244 
negative cells. CD14+ cells were stained for TLR expression.  245 
All stained cells were acquired using a FACScan (BD Biosciences, San Jose, CA) 246 
equipped with a 488nm laser and a 633nm laser upgrade.  Acquired events were analyzed using 247 
FlowJo software (Tree Star, Inc., Ashland, OR).   248 
 249 
Real-time PCR  250 
RNA was purified using the RNeasy Mini kit, including an on-column DNAse I digestion 251 
(Qiagen, Crawley, UK). cDNA was synthesized from 0.4µg of total RNA, using Superscript II 252 
reverse transcriptase and random hexamers in a total volume of 20 µl according to the 253 
manufacturer’s instructions (Invitrogen). cDNA was stored at -20°C until used in downstream 254 
real-time polymerase chain reaction (PCR). Oligonucleotide primers were designed using 255 
Primer3 as part of the Universal Probelibrary package (Roche).  256 
Primers for PRRs were as follows: TLR1 forward 5’-257 
CCTAGCAGTTATCACAAGCTCAAA-3’, reverse 5’- TCTTTTCCTTGGGCCAT TC-3’; 258 
TLR2 forward 5’- CGTTCTCTCAGGTGACTGCTC-3’, reverse 5’- CCTTT 259 
GGATCCTGCTTGC -3’; TLR3 forward 5’- AGTTGTCATCGAATCAAATTAAA GAG -3’, 260 
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11 
reverse 5’- AATCTTCCAATTGCGTGAAAA -3’; TLR5 forward 5’- GA 261 
CACAATCTCGGCTGACTG -3’, reverse 5’- GCCAGGAACATGAACATCAA -3’;  262 
TLR6 forward 5’- TGAGGTTAGCCTGCCAGTTAG -3’, reverse 5’- GCATTTACT 263 
CAAAAGAGACTGTTTCA -3’; TLR7 forward 5’- GCTAGACTGTCTCAAAAGA 264 
ACAAAAA -3’, reverse 5’- GCCCACACTCAATCTGCAC -3’; TLR8 forward 5’- 265 
GGGAGAATGAAGGAGTCATCTTT -3’, reverse 5’- TCAGCATTGACGACTGAA GG -3’; 266 
TLR9 forward 5’- TGTGAAGCATCCTTCCCTGT -3’, reverse 5’- 267 
GAGAGACAGCGGGTGCAG -3’; TLR10 forward 5’- TCTCAGCCCATCTCTGG ATT -3’, 268 
reverse 5’- TGGATTTCTTCCCGCATTTA -3’; Dectin1 forward 5’- CTTT 269 
CTCGGCCCCAGACT -3’, reverse 5’- TTGGGTAGCTGTGGTTCTGA -3’; Syk forward 5’- 270 
CGTCCACAACTTCCAGGTTC -3’, reverse 5’- AGGGGAGGACTTTC TGTGG -3’; Dectin2 271 
forward 5’- TTCAAGTCTCACCTGCTTCAGT -3’, reverse 5’- TCCAAGAAGCTGGGCAAC 272 
-3’.  273 
Relative quantitation of genes was performed using the ABI Prism 7900HT sequence 274 
detection system (Applied Biosystems, Foster City, CA, USA). TLR1,2,3,5,6,7,8,9,10, Dectin1, 275 
Syk and Dectin2  expressions  were determined using SYBR Green (Takara Bio Inc., Shiga, 276 
Japan) in accordance with the manufacturer’s suggested protocol. PCR mixtures contained 50% 277 
Sybr-Green PCR mix (Takara Bio Inc.)（50 nM (except 500nM for TLR3 and 10) of each primer 278 
and 3.2ng cDNA in a total volume of 20 µl. Conditions for PCR were as follows: 10 seconds at 279 
95°C, then 40 cycles each consisting of 5 seconds at 95°C and 30 seconds at 60°C, followed by a 280 
dissociation plot. To confirm that the amplification product was a single amplicon, products were 281 
analysed by agarose gel electrophoresis.  282 
TLR4 and CARD9 expression was determined using TaqMan Gene Expression Assays. 283 
PCR mixtures contained 50% TaqMan mastermix reagents (Sigma-Aldrich, St. Louis, MO, 284 
USA), 1µl of primer and probe mixture (assay ID Hs00152939_m1 for TLR4, Hs00364485_m1 285 
for CARD9, Applied Biosystems, Foster City, CA, USA), 1µl H2O and 3.2ng cDNA in a total 286 
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12 
volume of 20 µl.  Conditions for PCR were as follows: 2 minutes at 50°C, 10 minutes at 95°C, 287 
then following 40 cycles each consisting of 15 seconds at 95°C and 1 minute at 60°C. . 288 
The GAPDH gene was used as an endogenous control to normalise for differences in the 289 
amount of total RNA present in each sample; GAPDH TaqMan primers and probe were 290 
purchased from Applied Biosystems. TaqMan mastermix reagents (Sigma-Aldrich, St. Louis, 291 
MO, USA) were used according to the manufacturer’s protocol. Where data are presented, the 2
-
292 
(CT gene – CT GAPDH)
 (2
-∆CT
) calculation was used as an approximate measure of expression to allow 293 
comparison of expression levels between genes.  294 
 295 
Candida albicans 296 
Freeze-dried Candida albicans was purchased from American Type Culture Collection 297 
(#18804, Manassas, VA) and rehydrated according to the supplier’s instructions. Candida 298 
albicans was grown in autoclaved 1x broth (67g/L Yeast Nitrogen Base (YNB) and 10% D-299 
Glucose) at 30
o
C. Candida yeasts were propagated into hyphal forms in RPMI with 10% FCS at 300 
37oC and heat-killed before use in dendritic cell cultures. The concentration of Candida yeasts in 301 
YNB was determined to be 24.5x10
6
 by counting in a haemocytometer (10mg/ml protein 302 
content). Transformation of >98% yeasts into hyphae was confirmed by visual inspection under 303 
the microscope. Dense flasks of hyphae were decanted into newly-purchased sterile glass bottles 304 
and heated in a pressure cooker for 30 minutes at 120
o
C, based on previous titration experiment.  305 
Heat-killed Candida albicans was centrifuged at 400g for 10 minutes, and the supernatant was 306 
removed without disrupting the pellet.  The pelleted material was used in cell cultures at a final 307 
concentration of 1:10,000.   308 
Statistical analysis 309 
Results were analysed separately for groups of patients with a confirmed AIRE gene mutation 310 
(APECED), patients without a confirmed AIRE gene mutation (non-APECED) and healthy 311 
controls.  Statistical analysis were performed using the freely available software package R [19]. 312 
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13 
For each gene, we fitted a random effects model with treatment type, subgroups, age and patient 313 
as covariates. Interactions between treatment type and subgroups were also considered. Where 314 
necessary we transformed the expression level via a log or an square root transformation. 315 
Variables that were not statistically significant at the 0.05 level (based on the ANOVA results) 316 
were removed and the model was refitted. At each point of model fitting the residuals were 317 
examined to check that our assumptions were valid. To explore individual differences amongst 318 
subgroups and treatments we calculated adjusted p-values to control the family-wise error rate. 319 
Average values are presented as means +/- standard errors of the mean (SEM); level of 320 
significance was set at p<0.05. The graphical network in Figure 4 was calculated using graphical 321 
Gaussian models (GGMs) and shows partial correlations which took into account all available 322 
variables. Inclusion and exclusion of edges was determined using the method described by Drton 323 
and Perlman, 2003 [20]. 324 
Expression analysis and clustering were assessed with the GeneSpring, Agilent 325 
Technologies software. The data analysis for the clusters involved importing the data into 326 
GeneSpring and genes were clustered using a 5 cluster k-means with 100 iterations using a 327 
Pearson correlation for the similarity measure. 328 
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14 
RESULTS 329 
Percentages of monocytes, plasmocytoid and myeloid DC subsets in peripheral blood (ex 330 
vivo) from patients with CMC and controls 331 
In peripheral blood, monocytes, identified as CD14+ cells, showed significantly higher 332 
percentages in APECED and nonAPECED patients compared to controls (Table 1). There was 333 
no significant difference in percentages of myeloid and plasmocytoid DCs between controls, 334 
APECED and nonAPECED patients (Fig 1).  335 
 336 
Expression of TLR2 and TLR6 on monocytes ex-vivo 337 
The percentage and intensity of TLR2 and TLR6 expression was assessed on peripheral 338 
blood monocytes, defined as CD14+ cells. The percentage of TLR2+ CD14+ cells did not differ 339 
between patient groups and controls, but median fluorescence intensity (MFI) was significantly 340 
higher in APECED patients compared to controls and nonAPECED patients. Interestingly, non-341 
APECED patients had a significantly higher frequency of TLR6+CD14+ monocytes compared 342 
to both APECED patients and controls, although the MFI was comparable (Table 1). 343 
 344 
moDC mRNA expression of TLR 1, 4 and 6 (involved in protection against Candida) 345 
All groups had similar TLR1 mRNA expression in immature DCs. Healthy controls 346 
significantly downregulated TLR1 expression in response to all stimuli, in particular to LPS (Fig 347 
2A). As opposed to this, APECED and non-APECED CMC patients failed to downregulate 348 
TLR1 mRNA expression following stimulation with either CH or TLR2/6 ligand, although they 349 
did respond to LPS (Fig 2A). APECED and nonAPECED patients expressed lower levels of 350 
TLR4 mRNA in immature DCs compared to controls albeit not significantly. As opposed to 351 
controls where TLR4 was vigorously downregulated to all stimuli used, non-APECED patients 352 
did not respond to CH, while APECED patients did not respond to either CH or TLR2/6 ligand. 353 
They did however, respond to LPS (Fig 2B). An identical pattern to TLR1 was seen for TLR6 354 
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15 
(Fig 2C), i.e. controls downregulated mRNA expression in response to all stimuli used while 355 
APECED and non-APECED patients responded only to LPS.  356 
 In summary, healthy controls significantly downregulated TLR1, 4, and 6 mRNA 357 
expression in response to all stimuli used. As opposed to this, APECED and non-APECED CMC 358 
patients failed to downregulate TLR 1, 4, and 6 expression following stimulation with CH and / 359 
or TLR2/6 ligand, although the response to LPS stimulation was similar to controls. 360 
 361 
moDC mRNA expression of TLR 2 (with controversial role in protection against Candida) 362 
TLR2 mRNA in immature moDCs was readily detectable and comparable in both patient 363 
groups and controls. Interestingly, upon stimulation / maturation, healthy controls  364 
downregulated TLR2 expression only in response to LPS. CMC patients, both APECED and 365 
non-APECED failed to downregulate TLR2 in response to any of the stimuli (data not shown).  366 
 367 
moDC mRNA expression of TLR 3, 5 and 10 (not known to have a role in protection 368 
against Candida) 369 
TLR3 and TLR10 mRNA was detectable, but did not change in response to any of the 370 
stimuli used (data not shown). An unusual finding was the downregulation of TLR5 mRNA 371 
expression in healthy controls in response to all stimuli - CH, TLR2/6 ligand and LPS. Non-372 
APECED patients also responded to all 3 stimuli while APECED patients did not respond to any 373 
(data not shown).  374 
  375 
Dectin-1, Syk and CARD9 moDC mRNA expression 376 
Immature moDCs expressed readily detectable and comparable levels of mRNA in 377 
patients and controls. Dectin-1 mRNA levels in moDCs did not change in either healthy controls 378 
or CMC patients (both APECED and non-APECED) in response to CH or TLR2/6-ligand 379 
stimulation, but decreased significantly following LPS stimulation (Fig 3A). In contrast, healthy 380 
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16 
controls responded by decreasing Syk mRNA expression in response to all 3 stimuli. As 381 
opposed to this APECED patients only responded to LPS stimulation but not to either CH or 382 
TLR2/6-ligand. Non-APECED patients did not respond to TLR2/6-ligand stimulation but 383 
decreased their mRNA expression following stimulation with both CH and LPS (Fig 3B). 384 
Interestingly, healthy controls did not alter CARD9 expression except in response to LPS, as was 385 
also the case with APECED and non-APECED patients (Fig 3C). An additional finding was that 386 
in healthy controls, the levels of Dectin-1 mRNA increased significantly with age which was not 387 
seen in either APECED or non-APECED CMC patients (data not shown)  388 
 389 
moDCs TLR7, 8, 9 and Dectin-2 mRNA expression 390 
mRNA levels of TLR 7, 8, 9 and Dectin-2 were undetectable or borderline low in both 391 
immature and mature moDCs with all stimuli used.  392 
A summary of changes in mRNA PRR expression following stimulation in APECED, 393 
non-APECED patients and controls is given in Table 2.  394 
Based on the above results and data on cytokine production by these same moDCs 395 
previously published [15], we present a graphical dependency network (Fig 4) demonstrating the 396 
interactions between cytokine production and PRR expression by stimulated moDCs from CMC 397 
patients and healthy controls.  The network demonstrates the interdependence of cytokines and 398 
PRRs relevant for protective immunity to Candida, and highlights differences between CMC 399 
patients and healthy controls. It demonstrates that CMC patients lack the interaction found in 400 
healthy controls between TLR1, TLR4, TLR6 and Th1 cytokines IL-12/IL-23/IFNg/IL-2,  but 401 
have an interdependence of Dectin-1/Syk/CARD9 that is not evident in healthy controls. These 402 
findings suggest that the immune defect in CMC patients may lie in the interaction of TLR 1/4/6 403 
and Th1 cytokine production, which may be compensated by the Dectin-Syk-CARD9 pathway in 404 
CMC patients. 405 
 406 
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17 
Clustering analysis of PRRS and cytokines levels which were reported previously [15] 407 
showed associations for TLR1, 4, 6, Dectin-1, Syk, CARD9 (Set1), TLR2, 5, 10, interleukin 408 
(IL)-2, IL-10, IL-13 (Set2) and TLR7, 8, IL-6, IL-12, IL-23, IL27 (Set3), which did not differ 409 
significantly between healthy controls and patients (data not shown). 410 
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18 
DISCUSSION 411 
Candida infections range from benign, commensal colonisations of skin and mucous membranes 412 
in normal individuals to persistent, debilitating mucocutaneous infections (as seen in CMC 413 
patients) or life-threatening systemic candidemias with a significant mortality of over 30% in 414 
immunocompromised patients [16]. The role of the innate immune system in the protection 415 
against Candida has long been recognised, but was thought to be limited to first line 416 
phagocytosis and killing. More recently, it has become clear that the innate immune system not 417 
only distinguishes between various microorganisms, but through interactions with DCs, initiates 418 
and guides subsequent adaptive immune responses [21]. The crucial task of recognising invading 419 
pathogens and activating host responses is delivered by PRRs which recognise PAMPs on the 420 
microbes cell wall [3].   421 
 Most components of the fungal cell wall are not found in mammals and are thus ideal 422 
PAMPS for recognition of non-self. The core of the Candida albicans cell wall is made of 423 
polysaccharide fibrils composed of β-glucan  and chitin. The outer layer is made of proteins that 424 
are glycosylated with mannose - coined mannan or mannoprotein. These structures differ 425 
between fungi and are the major structures recognised my PRRs such as TLRs and CTLs [22]. 426 
 The role of TLRs in defence was first recognised in the Drosophila model of 427 
fungal infection [23]. Subsequent studies demonstrated that ligand recognition by TLRs induces 428 
differential activation of signalling cascades and leads to cytokine and chemokine production 429 
[24]. TLR2 and TLR6 were the first TLRs shown to be involved in recognition of a fungal 430 
structure – zymosan, derived from Saccharomyces cervisiae [17] and the adaptor MyD88, 431 
shared by all TLRs (except TLR3), was repeatedly confirmed to be crucial for fungal defence in 432 
mice.  At least 4 TLRs (TLR2, TLR2, TLR4, TLR6) are involved in triggering cytokine 433 
production by Candida albicans. Recognition of Candida at the cellular level is mediated by 434 
TLRs and CTL receptors [25]. TLR4 induces mainly pro-inflammatory signals through the 435 
MyD88 dependent pathway, leading to activation of nuclear factor (NF)-κB, mitogen-activated 436 
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19 
protein (MAP)-kinases and interferon-releasing factor 3 (IRF3), stimulating Th1 responses 437 
through production of IL-12, IFNγ, tumour necrosis factor (TNFα) and type 1 IFNs, resulting in 438 
efficient elimination of Candida infection. In contrast, binding of Candida to TLR2 leads to 439 
production of transforming growth factor (TGF)β and IL-10, leading to tolerance, 440 
immunosuppresion and generation of T-regulatory cells [26]. However, TLR2 is also able to 441 
associate with Dectin-1 in the induction of pro-inflammatory responses [27]. In CMC patients, 442 
we previously demonstrated low IL-12 and very high IL-10 and IL-6 production by PBMCs [28], 443 
with low IL-23 and high IL-6 responses by moDCs [15]. The results in our current study show 444 
normal expression of TLRs and CTLs on immature moDCs but inadequate downregulation of 445 
TLR1, 4 and 6, suggesting defects in signalling pathways downstream of these receptors. More 446 
recent data suggests TLR9 can recognise fungal  DNA, but the importance of this in fungal 447 
defence is still not clear [3]. Whether any of these pathways is directly involved or impacts on 448 
other signalling pathways such as Dectin-1 is unclear, as would be suggested by our ongoing 449 
studies which have demonstrated markedly reduced IL-17 production in non-APECED (but not 450 
APECED) patients [29]. AIRE gene mutations hav  also been shown to critically downregulate 451 
immunological pathways in DCs from APECED patients [30], suggesting that this mechanism 452 
may be involved in impaired immune responses to Candida. However, AIRE gene mutations 453 
may affect DC function in alternative ways, such as increasing antigen-presentation to T cells 454 
[31] or interfering with T-regulatory cell induction / function, as has been demonstrated [32, 33]. 455 
Recently, patients with MyD88 deficiency were reported to suffer with pyogenic 456 
infections, including invasive pneumococcal diseases, but were otherwise healthy. Our patients 457 
with CMC did not suffer with severe, life-threatening infections caused by pyogenic bacteria, 458 
although a previous report in children with CMC demonstrated a high incidence of bacterial 459 
infection and mortality from non-Candida infections [34]. 460 
Mannose-binding lectin (MBL) is a soluble C-type lectin receptor that binds Candida and 461 
other microorganisms, promoting complement deposition. Low levels of MBL in humans 462 
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20 
predispose to infections, althought MBL-deficient mice do not show increased susceptibility to 463 
infections with Candida [35]. There is some evidence for a role of MBL in recurrent 464 
vulvovaginal candidiasis [36], but its’ importance – if any – in CMC is not clear. 465 
In this study, we show for the first time that patients with CMC, both APECED and non-466 
APECED have normal frequencies of both myeloid and plasmocytoid DC subsets in peripheral 467 
blood, indicating that a major lack of these cells is not responsible for their increased 468 
susceptibility to Candida infections. The higher frequency of blood monocytes in CMC patients 469 
(both APECED and nonAPECED) might be due to ongoing Candida-induced inflammation. 470 
Almost all monocytes in both patients and controls expressed TLR2, which was upregulated in 471 
APECED patients. Interestingly, TLR6 was expressed on almost all monocytes in non-APECED 472 
patients but not in the other groups. These findings argue against an intrinsic defect in TLR2 and 473 
TLR6 expression on monocytes in CMC patients as and underlying cause of their increased 474 
susceptibility to Candida infections.  475 
In our study, TLR1, 4, 6, 2 and TLR5 mRNA was expressed in immature moDCs in all 476 
patients and controls and the level of expression did not differ significantly between groups. This 477 
is the first study to report that expression of these TLRs in immature myeloid DCs of APECED 478 
and non-APECED CMC patients is normal.  479 
Previous studies have demonstrated that when moDCs are induced to mature by 480 
stimulation with pathogens or pathogen PAMPS, levels of TLR mRNA decrease or disappear, as 481 
opposed to macrophages and monocytes [37] where TLR mRNA increases. In healthy 482 
individuals, decreased mRNA expression was reported already 2h after stimulation but was most 483 
obvious after 24h ([38], suggesting that decreased levels of TLR mRNA are consistent with 484 
normal DC maturation dynamics. In our study, we found that healthy controls downregulated 485 
TLR1, 4, 6 and 5 in response to all stimuli used (CH, TLR2/6 ligand and LPS). In contrast 486 
APECED patients responded only to LPS and did not downregulate TLR1, 4, 6 and 5 mRNA  487 
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21 
expression when stimulated with either CH or TLR2/6 ligand. Non-APECED patients similarly 488 
failed to downregulate TLR1 and TLR6, but they did downregulate TLR4 in response to TLR2/6 489 
ligand (but not CH) and downregulated TLR5 in response to all stimuli, similarly to controls. On 490 
the other hand TLR2 expression in healthy controls changed only in response to LPS but no 491 
change was seen following CH or TLR2/6 ligand stimulation. In APECED and non-APECED 492 
patients, TLR2 mRNA expression did not change in response to any of the stimuli used. In 493 
summary, when stimulated with Candida and Candida-like stimuli, APECED patients did not 494 
downregulate any of the TLRs known to be involved in anti-Candida responses (TLR1, 4, 6, 2), 495 
while non-APECED patients downregulated only TLR4 in response to TLR2/6 ligand. These 496 
findings suggest that moDCs in both APECED and non-APECED patients have normal patterns 497 
of mRNA TLR expression in immature DCs, but that progression to maturation is altered, 498 
particularly in response to Candida and Candida-like stimuli, suggesting impaired maturation of 499 
DCs in these patients.  500 
The results reported in this paper were part of a larger study which included assessment 501 
of a range of cytokines produced (IL-12p70, IL-23, IFNγ, IL-2, TNFα, IL-6, TGFβ, IL-10, IL-5, 502 
IL-13) as well as cell-surface maturation marker expression (CD83, CD86, HLA-DR) by the 503 
same dendritic cells on which PRR expression was assessed, recently published [15]. These 504 
results demonstrated that in both APECED and non-APECED CMC patients, DC function was 505 
impaired as evidenced by altered cytokine expression profiles and DC maturation/activation: 1) 506 
both groups over-produce IL-2, IFNγ, TNFα, IL-13 and demonstrated impaired DC maturation. 507 
2) Only non-APECED patients showed markedly decreased Candida-stimulated production of 508 
IL-23 and markedly increased production of IL-6, suggesting impairment of the IL-6/IL-23/Th17 509 
axis. 3) In contrast, only APECED patients showed DC hyper-activation, which may underlie 510 
altered T-cell responsiveness, autoimmunity and impaired response to Candida.  The altered 511 
cytokine production may well be linked to the altered PRRs downregulation in maturing DCs in 512 
particular TLR 1, 4 and 6 which are known to be involved in Candida responses. 513 
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22 
The interdependence of cytokines and PRRs relevant for protective immunity to 514 
Candida in CMC patients and healthy controls is also demonstrated in Fig 4. Amazingly, it 515 
shows that CMC patients lack the interaction found in healthy controls between TLR1/4/ 6 and 516 
Th1 cytokines IL-12/IL-23/IFNg/IL-2, but demonstrate an interdependence of Dectin-517 
1/Syk/CARD9 that is not evident in healthy controls, possibly as a compensatory mechanism. 518 
An unexpected and unexplained finding is the downregulation of TLR5 mRNA in both 519 
healthy controls and non-APECED patients to CH, TLR2/6, suggesting that TLR5 may be 520 
involved in recognition of Candida PRRs, which has not been observed previously. 521 
Alternatively, “cross-talk” among TLRs and their ligands can be involved, where microbial 522 
PAMPs are able to affect mRNA and protein expression of different TLRs. It was reported that 523 
in addition to flagellin which is the known TLR5 ligand, unrelated PAMPs such as peptidogycan 524 
can exert a general stimulatory activity on TLR5 expression [39]. 525 
Dectin-1, Syk and CARD9 mRNA levels in immature moDCs were readily detectable in 526 
all groups. Both CMC patients and healthy controls showed a robust downregulation in response 527 
to LPS, but less so to Candida or TLR2/6 ligand stimulation, where patients actually responded 528 
more robustly than controls. This was surprising given the important role of the Dectin-1, Syk 529 
and CARD9 pathway in fungal immune responses [40]. A possible explanation is the lack of β-530 
glucan on the surface of Candida hyphae as opposed to yeasts, as previously reported [27] which 531 
is necessary for the engagement of Dectin-1.  Dectin-1 binds β-glucans on the Candida cell wall 532 
and activates the Syk-CARD9 signalling pathway [41],  leading to production of IL-17, which is 533 
increasingly thought to be of major importance in protection against Candida infection  [9]. 534 
Recently, a homozygous mutation in the CARD9 gene was reported in a family where patients 535 
suffered with recurrent oral and vaginal candidiasis, but in contrast to classical CMC, suffered 536 
with other fungal (dermatophyte) infections as well [42]. The relevance of this finding for 537 
patients with classical CMC (which were investigated in this study) is under investigation, 538 
although our results demonstrate that both APECED and non-APECED CMC patients responded 539 
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23 
to Candida by downregulating CARD9. Interestingly, the network connectivity analysis in our 540 
study (Fig 4) actually suggests that the Dectin-1-Syk-CARD9 pathway was of greater relevance 541 
for Candida responses in our CMC patients than in healthy controls.  542 
 In summary, we have demonstrated that CMC patients, with or without APECED do not 543 
lack plasmocytoid or myeloid dendritic cells in blood, nor do they harbour defects of monocyte-544 
TLR expression, relevant for anti-Candida responses. In immature moDCs, levels of mRNA 545 
expression for all PRRs involved in anti-Candida responses (TLR1, 2, 4, 6, Dectin-1, Syk, 546 
CARD9) were comparable to normal controls, strongly suggesting that defects in PRR 547 
expression are unlikely to be responsible for the increased susceptibility to Candida infections in 548 
these patients.  However, both groups of CMC patients (APECED patients in particular), fail to 549 
downregulate PRR mRNA expression in response to Candida stimulation, implying defective 550 
DC maturation, possibly involving defective TLR and/or CTL signalling, which could be 551 
responsible for inadequate Candida handling seen in these patients. Further investigation of TLR 552 
and CTL signalling pathways will elucidate putative defects in CMC patients which may 553 
underlie their inability to clear Candida. 554 
 555 
 556 
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29 
Table 1. Whole blood myeloid (my) and plasmocytoid (p) dendritic cell (DC) percentages 669 
and expression of TLR2 and TLR6 on CD14+ monocytes. 670 
 APECED Non- 
APECED 
Controls APECED Non- 
APECED 
Controls 
 Percentage - % Median Fluorescence Intensity - 
MFI 
CD14+ 7.6** 
(±0.4) 
8.0 ** 
 (±0.7) 
6.3 
(±0.6) 
NA NA NA 
TLR2 97  
(±1.5) 
95  
(±1.3) 
93  
(±2.4) 
193*  
(±21) 
160  
(±9) 
142 
(±19) 
TLR6 83  
(±6) 
96**  
(±1) 
74  
(±8) 
27  
(±8) 
16  
(±2) 
14  
(±2) 
myDCs 0.54  
(±011) 
0.46 
(±0.01) 
0.52 
(±0.06) 
pDCs 0.10 
(±0.02) 
0.07 
(±0.01) 
0.10 
(±0.01) 
DCs in whole blood were identified as HLA-DR positive, CD11c (myDCs) or CD123 (pDCs) 671 
positive, CD3, CD14, CD19 negative cells. Monocytes, identified as CD14+ cells were stained 672 
for TLR expression. Numbers are Means ±SEM. NA = not applicable; *p=0.03, ** = p=0.02;  673 
Page 62 of 68Clinical Experimental Immunology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
  
 
 
 
30 
Table 2. Summary of TRL/PRR mRNA expression in APECED, non-APECED patients 674 
and healthy controls 675 
 APECED Non- 
APECED 
Controls APECED Non- 
APECED 
Controls APECED Non- 
APECED 
Controls 
 Candida hyphae TLR 2/6 ligand LPS 
TLR1   → → ↓ → → ↓ ↓ ↓ ↓ 
TLR4 → → ↓ → ↓ ↓ ↓ ↓ ↓ 
TLR6 → → ↓ → → ↓ ↓ ↓ ↓ 
TLR2 → → → → → → → → ↓ 
 
Dectin-1 → → → → → → ↓ ↓ ↓ 
Syk → ↓ ↓ → → ↓ ↓ → ↓ 
CARD9 → → → → ↓ → ↓ ↓ ↓ 
 
TLR5 → ↓ ↓ → ↓ ↓ → ↓ ↓ 
TLR3 → → → → → → → → → 
TLR10 → → → → → → → → → 
Immature mDC were stimulated with Candida albicans hyphae, a specific TLR2/6 ligand or 676 
LPS.  After 24h, RNA was extracted from mDCs and processed for mRNA PCR analysis.  677 
Arrows indicate statistically significant increases (↑), decreases (↓) or no changes (→ ) of 678 
mRNA expression  compared to levels in unstimulated mDCs. mRNA for TLR7/8/9 and Dectin-679 
2 was undetectable (not shown). 680 
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Figure legends 681 
Figure 1.  Representative flow-cytometry plots of whole blood stains. Whole blood was 682 
stained directly with antibodies to various cell surface molecules and appropriate isotype 683 
controls, lysed, washed and fixed as described. Cells were acquired using a FACScan (BD 684 
Biosciences, San Jose, CA) and analysed using FlowJo software (Tree Star, Inc., Ashland, OR).  685 
A & B: Myeloid (my) and plasmocytoid (p)DCs flow cytometry dot-plots ex-vivo. *myDCs 686 
were identified as HLA-DR/CD11c positive, CD3/CD14/CD19 negative cells (1.31% of total 687 
lymphocyte population and 15.8% of CD11c/HLA-DR positive cells on graph shown). **pDCs 688 
were identified as CD123/HLA-DR positive, CD3/CD14/CD19 negative cells (0.25% of total 689 
lymphocyte polulation and 3.01% of CD123/HLA-DR positive cells on graph shown). C & D: 690 
Flow-cytometry histograms of frequency (%) and median fluorescence intensity (MFI) of 691 
TLR2+ or TLR6+ monocytes in peripheral blood. CD14+ cells were stained for TLR 692 
expression. (92% CD14/TLR2 positive and 79% CD14/TLR6 positive on graphs shown). 693 
Negative peaks represent appropriate isotype controls.   694 
 695 
Figure 2. mRNA expression of TLR 1, 4, and 6 in moDCs from CMC patients with or 696 
without APECED and controls following stimulation with CH, TLR2/6 ligand and LPS 697 
(means +/- SEM). Immature moDCs from patients and controls were either left unstimulated or 698 
treated with Candida albicans hyphae, a specific TLR2/6 ligand or LPS. Immature moDCs from 699 
CMC patients demonstrate normal mRNA expression whereas downregulation after stimulation 700 
with CH and TLR2/6 is impaired. 701 
 702 
Figure3. mRNA expression of Dectin-1, Syk and CARD9 in moDCs from CMC patients 703 
with or without APECED and controls following stimulation with CH, TLR2/6 ligand and 704 
LPS (means +/- SEM). Immature moDCs from patients and controls were either left 705 
unstimulated or treated with Candida albicans hyphae, a specific TLR2/6 ligand or LPS. 706 
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32 
Immature moDCs from both CMC patients and controls have detectable mRNA expression 707 
whereas downregulation after stimulation with CH and TLR2/6 is seen only with Syk. 708 
  709 
Figure 4. Graphical dependency network describing interactions between cytokine 710 
production and PRR expression on moDCs from CMC patients and healthy controls, 711 
relevant for protective immunity against Candida.  The graphical network was calculated 712 
using graphical Gaussian models (GGMs). Each line indicates significant partial correlations 713 
between genes. Black lines denote connections on networks for both CMC patients and healthy 714 
controls. Red lines denote connections on network for healthy controls only. Blue lines denote 715 
connections on network for CMC patients only. The network shows that CMC patients lack the 716 
interactions found in healthy controls between TLR1, TLR4, TLR6 and Th1 cytokines IL-12/IL-717 
23/IFNg/IL-2 (marked in red), but intriguingly demonstrate an interdependence of Dectin-718 
1/Syk/CARD9 (marked in blue) that is not evident in healthy controls.  719 
 720 
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